For the Culture By The Culture. ISSN: 3064-9331.
Massachusetts Question 8 would end recreational cannabis sales, repeal adult home-grow protections, and leave limited possession legal. Pot Culture Magazine follows the weed, the jobs, the tax revenue, and the consumers caught in the middle, asking the question the repeal campaign cannot escape: if Massachusetts kills the legal retail market, who supplies the cannabis that adults may still possess?
Pot Culture Magazine launches YOU CAN’T MAKE THIS SHIT UP, a new weekly series built from completely true cannabis stories too absurd to invent. The debut follows Irvin Rosenfeld, the federal patient who received a wax-sealed tin containing 300 government joints while Washington continued insisting marijuana had no accepted medical use.
Can Georgia mail medical cannabis directly to registered patients? The state’s proposed delivery rule names USPS and private carriers, but federal postal requirements still demand answers about prescriptions, packaging, vaping products, and DEA registration. Pot Culture Magazine follows the legal route from Georgia’s Commission to Publication 52 and finds where the package could stop.
California’s new cannabis license split lets one dispensary separate medical cannabis treated as Schedule III from recreational cannabis that remains Schedule I. Pot Culture Magazine found DCC’s public guidance may keep both businesses tied to the same track-and-trace account, complicating the clean separation operators may need for federal registration and relief from Section 280E.
Kentucky’s Hospital Cannabis Problem exposes the gap between medical cannabis approval and bedside access. Kentucky now recognizes terminal illness in its program. However, hospitals, hospices, nursing homes, and other care settings may still decide whether patients can use cannabis where pain, fear, and end-of-life care are happening.
France keeps extending medical cannabis access while politically resisting broader legalization. Pot Culture Magazine examines the country’s cautious framework, frozen patient access, regulatory delays, and the growing contradiction between public rhetoric and the reality of cannabis reform already unfolding inside France.